Technology area: Biotechnology & Pharmaceuticals
8 pending office actions • 6 art units • 8 examiners • 0 of 8 (0%) have an AI response strategy ready • 7 patents granted in the last 365 days
Sigilon Therapeutics Inc. has 8 pending office actions in Biotechnology & Pharmaceuticals. The matters are distributed among 8 examiners and 6 art units, creating a broad prosecution footprint across the technology area.
LANKFORD JR, LEON B is the busiest examiner, with 1 pending matter. Because the listed examiner assignments are individually limited, portfolio management should prioritize consistent disclosure and claim strategy rather than relying on one examiner relationship.
The art-unit distribution means counsel may encounter different approaches to related technical subject matter. A centralized review of claim terminology, support, and amendment boundaries can reduce inconsistency across responses while preserving arguments suited to each record.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (38%) |
| Double-patenting + other | 1 (12%) |
| Multi-statute (no §101) | 4 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| LANKFORD JR, LEON B | 1 | 70.1% | +31.4% |
| LEE, HOI YAN NMN | 1 | 38.5% | +74.9% |
| NATARAJAN, MEERA | 1 | 62.7% | +17.8% |
| CANELLA, KAREN A | 1 | 62.3% | +32.8% |
| THUESON, HANNA MARIE | 1 | 79.4% | +26.1% |
| CHANDRAKUMAR, NIZAL S | 1 | 72.6% | +18.3% |
| WILSON, MICHAEL C | 1 | 41.5% | +17.8% |
| WEIDNER, ADAM M | 1 | 63.8% | +33.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 18932580 | IMPLANTABLE PARTICLES AND RELATED METHODS | LANKFORD JR, LEON B | — |
| 18724813 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | LEE, HOI YAN NMN | — |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 215d overdue |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 29d overdue |
| 18932580 | IMPLANTABLE PARTICLES AND RELATED METHODS | LANKFORD JR, LEON B | — |
| 18724813 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | LEE, HOI YAN NMN | — |
| 18705759 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | NATARAJAN, MEERA | — |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | — |
| 18274134 | BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS | THUESON, HANNA MARIE | — |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | — |
| Art Unit | Apps |
|---|---|
| 1643 | 2 |
| 1638 | 2 |
| 1657 | 1 |
| 1693 | 1 |
| 1625 | 1 |
| 1675 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18932580 | IMPLANTABLE PARTICLES AND RELATED METHODS | LANKFORD JR, LEON B | 1657 | §103§112 | Non-Final OA | — | Pending | Oct 30, 2024 |
| 18724813 | MODIFIED POLYSACCHARIDE POLYMERS AND RELATED COMPOSITIONS AND METHODS THEREOF | LEE, HOI YAN NMN | 1693 | §103§112Other | Non-Final OA | — | Pending | Jun 27, 2024 |
| 18705759 | COMPOSITIONS FOR CELL-BASED THERAPIES AND RELATED METHODS | NATARAJAN, MEERA | 1643 | §103 | Non-Final OA | — | Pending | Apr 29, 2024 |
| 18274123 | COMPOSITIONS, DEVICES AND METHODS FOR TREATING IMMUNE-MEDIATED INFLAMMATORY DISEASES | CANELLA, KAREN A | 1643 | §103§112 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 18274134 | BIOCOMPATIBLE DEVICES FOR CELL-BASED THERAPIES AND RELATED METHODS | THUESON, HANNA MARIE | 1638 | §103 | Non-Final OA | — | Pending | Jul 25, 2023 |
| 17784972 | COMPOUNDS, POLYMERS, DEVICES, AND USES THEREOF | CHANDRAKUMAR, NIZAL S | 1625 | §103DP | Final Rejection | 29d overdue | Pending | Jun 13, 2022 |
| 17598154 | COMPOSITIONS, DEVICES, AND METHODS FOR FACTOR VII THERAPY | WILSON, MICHAEL C | 1638 | §103§112 | Non-Final OA | 215d overdue | Pending | Sep 24, 2021 |
| 16651892 | METHODS, COMPOSITIONS, AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS | WEIDNER, ADAM M | 1675 | §103Other | Final Rejection | — | Pending | Mar 27, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSigilon Therapeutics Inc. has 8 pending office actions as of November 2026, spread across 6 art units and 8 examiners.
Leon B Lankford Jr. has the most, with 1 of Sigilon Therapeutics Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.